Welcome to Cerba Research’s oncology articles series, where the latest breakthroughs in oncology innovation meet actionable strategies dedicated to your R&D programs from preclinical discovery through Phase III trials. Dive into these articles to uncover how cutting-edge actualities, like ADC advancements, NGS-driven resistance tracking, and precision biomarker assays, can sharpen your trial designs, mitigate risks, and accelerate precision medicine development. Benefit from real-world expertise that positions your oncology projects for success, complete with Cerba Research’s specialized laboratory solutions tailored to overcome today’s toughest challenges in immuno-oncology, spatial profiling, and beyond.
